Lupin Gets FDA nod to Market Ulcerative Colitis Tablets in US

Get Two Days Free Trial from here and work with us click herehttp://www.ripplesadvisory.com

Drug firm Lupin has received tentative approval from the US health regulator to market its Balasalazide Disodium tablets, used for treatment of ulcerative colitis, in the American market. 

The company has received tentative approval to market its Balasalazide Disodium tablets 1.1 gm from the United States Food and Drug Administration (USFDA), Lupin said in a BSE filing today.

The company's product is generic version of Salix Pharmaceuticals Inc's Giazo tablets in the same strength, it added. "Giazo tablets had the US sales of USD 0.79 million (IMS MAT September 2016)," Lupin said. Balasalazide Disodium tablets are indicated for the treatment of mildly to moderately active ulcerative colitis in male patients 18 years of age and older, it added.

Comments

Popular posts from this blog

Daily equity Market By Ripplesadvisory Report 16-Aug-2016

सकारात्मक वैश्विक रुझानों के सहारे बाजार में मजबूती, निफ्टी 10,900 के ऊपर

11-year data suggests bears control D-Street in September; can bulls defy odds?